BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35665761)

  • 1. Cdkl5 mutant zebrafish shows skeletal and neuronal alterations mimicking human CDKL5 deficiency disorder.
    Varela T; Varela D; Martins G; Conceição N; Cancela ML
    Sci Rep; 2022 Jun; 12(1):9325. PubMed ID: 35665761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
    Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ
    Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel preclinical model for CDKL5 deficiency disorder.
    Serrano RJ; Lee C; Douek AM; Kaslin J; Bryson-Richardson RJ; Sztal TE
    Dis Model Mech; 2022 Mar; 15(3):. PubMed ID: 34913468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
    Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
    Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
    Terzic B; Cui Y; Edmondson AC; Tang S; Sarmiento N; Zaitseva D; Marsh ED; Coulter DA; Zhou Z
    Neurobiol Dis; 2021 Jan; 148():105176. PubMed ID: 33197557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
    Yennawar M; White RS; Jensen FE
    J Neurosci; 2019 Jun; 39(24):4814-4828. PubMed ID: 30952813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
    Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
    Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Providing quality care for people with CDKL5 deficiency disorder: A European expert panel opinion on the patient journey.
    Amin S; Møller RS; Aledo-Serrano A; Arzimanoglou A; Bager P; Jóźwiak S; Kluger GJ; López-Cabeza S; Nabbout R; Partridge CA; Schubert-Bast S; Specchio N; Kälviäinen R
    Epilepsia Open; 2024 Jun; 9(3):832-849. PubMed ID: 38450883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with a GSK-3β/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of
    Loi M; Gennaccaro L; Fuchs C; Trazzi S; Medici G; Galvani G; Mottolese N; Tassinari M; Giorgini RR; Milelli A; Ciani E
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
    Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S
    J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling.
    Zhu ZA; Li YY; Xu J; Xue H; Feng X; Zhu YC; Xiong ZQ
    Cell Rep; 2023 Oct; 42(10):113202. PubMed ID: 37777961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voluntary Running Improves Behavioral and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder.
    Mottolese N; Uguagliati B; Tassinari M; Cerchier CB; Loi M; Candini G; Rimondini R; Medici G; Trazzi S; Ciani E
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with FRAX486 rescues neurobehavioral and metabolic alterations in a female mouse model of CDKL5 deficiency disorder.
    Fuchs C; Cosentino L; Urbinati C; Talamo MC; Medici G; Quattrini MC; Mottolese N; Pietraforte D; Fuso A; Ciani E; De Filippis B
    CNS Neurosci Ther; 2022 Nov; 28(11):1718-1732. PubMed ID: 35932179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder.
    Tassinari M; Mottolese N; Galvani G; Ferrara D; Gennaccaro L; Loi M; Medici G; Candini G; Rimondini R; Ciani E; Trazzi S
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Touchscreen cognitive deficits, hyperexcitability and hyperactivity in males and females using two models of Cdkl5 deficiency.
    Adhikari A; Buchanan FKB; Fenton TA; Cameron DL; Halmai JANM; Copping NA; Fink KD; Silverman JL
    Hum Mol Genet; 2022 Sep; 31(18):3032-3050. PubMed ID: 35445702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mGluR5 PAMs rescue cortical and behavioural defects in a mouse model of CDKL5 deficiency disorder.
    Gurgone A; Pizzo R; Raspanti A; Chiantia G; Devi S; Comai D; Morello N; Pilotto F; Gnavi S; Lupori L; Mazziotti R; Sagona G; Putignano E; Nocentini A; Supuran CT; Marcantoni A; Pizzorusso T; Giustetto M
    Neuropsychopharmacology; 2023 May; 48(6):877-886. PubMed ID: 35945276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral impulsivity is associated with pupillary alterations and hyperactivity in CDKL5 mutant mice.
    Viglione A; Sagona G; Carrara F; Amato G; Totaro V; Lupori L; Putignano E; Pizzorusso T; Mazziotti R
    Hum Mol Genet; 2022 Nov; 31(23):4107-4120. PubMed ID: 35861639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A GABA
    Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E
    Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
    Vitorino M; Cunha N; Conceição N; Cancela ML
    Mol Biol Rep; 2018 Aug; 45(4):445-451. PubMed ID: 29752575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
    Trovò L; Fuchs C; De Rosa R; Barbiero I; Tramarin M; Ciani E; Rusconi L; Kilstrup-Nielsen C
    Neurobiol Dis; 2020 May; 138():104791. PubMed ID: 32032735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.